About Pacific Shuanglin Bio-pharmacy Company

The company was listed on the Shenzhen Stock Exchange with the approval of the China Securities Regulatory Commission on June 28, 1996. After some column changes, the company changed its name to its current name on March 30, 2021. The company's main business is research, development, production and sales of blood products. Main products: human blood albumin, human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, human immunoglobulin for tetanus, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, intravenous hepatitis B human immunoglobulin (pH4), freeze-dried intravenous human immunoglobulin (pH4), human prothrombin complex, etc. The company won the honor of the Two Integrated Management System Assessment Class A Certificate and the Heilongjiang Digital (Intelligent) Demonstration Workshop; Guangdong Shuanglin won the Zhanjiang Water Saving Enterprise Award; the Dual Integrated Management System Assessment Class A Certificate; the Heilongjiang Digital (Intelligent) Demonstration Workshop; and the Zhanjiang Water Saving Enterprise Honor.